Novo Nordisk A-S

Yahoo Finance • 2 hours ago

Prothena Announces up to $100 Million Share Repurchase Plan

DUBLIN, February 27, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announce... Full story

Yahoo Finance • 5 hours ago

Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) has now surrendered the last of the gains that followed the 2021 US approval of Wegovy, marking a decisive turn in what had been one of Europe's most powerful pharmaceutica... Full story

Yahoo Finance • 5 hours ago

Inflation Surprise Jolts Wall Street

This article first appeared on GuruFocus. The S&P 500 (SP500) stumbled out of the gate Friday after a hotter than expected wholesale inflation report reminded investors that price pressures are not cooling as smoothly as hoped. Wall Stre... Full story

Yahoo Finance • 11 hours ago

Hims Faces GLP-1 Scrutiny While Broader Telehealth Growth Story Evolving

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Hims & Hers Health (NYSE:HIMS) is facing a patent infringement lawsuit from Novo Nordisk over its compounded weight loss drugs. Th... Full story

Yahoo Finance • 12 hours ago

12 Press Releases You Need to See This Week

Including Warner Bros. Discovery's response to Paramount's latest offer, TIME's Women of the Year and Panera's first value menu. Plus, a recap of the week's big earnings and headlines ahead of MWC 2026. NEW YORK, Feb. 27, 2026 /PRNewswi... Full story

Yahoo Finance • 12 hours ago

Novo Nordisk’s Torrid Week Erases Last of Wegovy-Fueled Gains

Photographer: George Frey/Bloomberg (Bloomberg) -- The weight loss-fueled gains of Danish drugmaker Novo Nordisk A/S are officially a thing of the past. The stock this week wiped out the last of the yearslong surge that followed the 2021... Full story

Yahoo Finance • 17 hours ago

RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best GARP Stocks to Buy According to Analysts.RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market On February 25, RBC Capital initiated coverage of... Full story

Yahoo Finance • 22 hours ago

Novo Nordisk Pipelines Oral Obesity Drugs As Shares Face Steep Pressure

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) has entered a new $2.1b partnership with Vivtex to develop next generation oral biologic drugs for obes... Full story

Yahoo Finance • yesterday

Jim Cramer Recommends Eli Lilly over Novo Nordisk

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Answering a caller’s question about the stock during the lightning round, Cramer said: Oh no, you don’t want to be in Novo Nordisk. You want to be in Eli Lilly. Nov... Full story

Yahoo Finance • yesterday

Anthropic Excites But Doesn't Replace

This article first appeared on GuruFocus. Anthropic's latest product showcase got people talking about AI replacing enterprise software, but Wedbush thinks those fears are getting ahead of reality. At its Enterprise Agents event, Anthrop... Full story

Yahoo Finance • 2 days ago

Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S(NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G)... Full story

Yahoo Finance • 2 days ago

Novo Nordisk Resets Obesity Strategy After CagriSema Miss And Vivtex Deal

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk's CagriSema weight loss drug missed its main target in a key phase 3 trial, falling s... Full story

Yahoo Finance • 2 days ago

Novo Partners Vivtex in Deal Worth Up to $2.1 Billion

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) has moved to reinforce its long-term growth narrative, announcing a partnership with US biotech Vivtex Corp. that could be worth up to $2.1 billion as it seeks to expand it... Full story

Yahoo Finance • 2 days ago

Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs

This article first appeared on GuruFocus. Novo Nordisk A/S (NVO, Financials) has agreed to a partnership worth up to $2.1 billion with Boston-based Vivtex Corporation to develop next-generation oral biologic therapies targeting obesity, d... Full story

Yahoo Finance • 2 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Wedbush says Anthropic demos strong, software-replacement hype overdone

Wedbush notes Anthropic hosted its Enterprise Agent event where the company provided the latest product updates that make Claude Cowork effective for enterprises. The company provided some use cases across different industries, including S... Full story

Yahoo Finance • 2 days ago

Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact

Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks.Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact On February 24, BofA said Novo Nordisk’s decision to... Full story

Yahoo Finance • 2 days ago

BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update

BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as... Full story

Yahoo Finance • 2 days ago

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NY... Full story

Yahoo Finance • 2 days ago

Anthropic product event shows competition risk to software overblown: Wedbush

[Wall Street Christmas Tree] cmart7327 Following Anthropic's (ANTHRO [https://seekingalpha.com/symbol/ANTHRO]) product event, Wedbush (IVES [https://seekingalpha.com/symbol/IVES]) said that competition risk to software is overblown. Anal... Full story